TABLE 2.
Analysis of the different treatments
| Treatment parametera | Value for the parameterc |
P value | ||
|---|---|---|---|---|
| Total patient population (n = 77) | Conventional-dose group (n = 36) | Low-dose group (n = 41) | ||
| Duration from PCP onset to treatment (days) | 6.1 ± 5.2 | 6.3 ± 4.3 | 5.9 ± 5.9 | 0.26 |
| TMP-SMX treatment | ||||
| Correction dose (mg/kg TMP) | 14.0 ± 4.1 | 17.5 ± 1.9 | 10.8 ± 2.8 | <0.001 |
| Duration of TMP-SMX therapy (days) | 16.9 ± 6.6 | 15.7 ± 6.1 | 18.1 ± 6.8 | 0.06 |
| Occurrence of adverse eventsb | 22 (28.6) | 15 (41.7) | 7 (17.1) | 0.02 |
| Dose reductiond | 15 (19.5) | 8 (22.2) | 7 (17.1) | 0.57 |
| Withdrawal or change to second-line regimend | 10 (13.0) | 7 (19.4) | 3 (7.3) | 0.22 |
| Second-line regimen | ||||
| Pentamidine | 6 (7.8) | 5 (13.9) | 1 (2.4) | 0.06 |
| Atovaquone | 1 (1.3) | 0 (0) | 1 (2.4) | 0.35 |
| ICU admission | 23 (29.9) | 9 (25.0) | 14 (34.1) | 0.38 |
| Mechanical ventilation | 25 (32.5) | 11 (30.6) | 14 (34.1) | 0.74 |
| Adjunctive corticosteroid therapy | 55 (71.4) | 26 (72.2) | 29 (70.7) | 0.89 |
a
CTCAE, Common Terminology Criteria for Adverse Events; ICU, intensive care unit; PCP, pneumocystis pneumonia; TMP-SMX, trimethoprim-sulfamethoxazole.
b
CTCAE grade of ≥3.
c
Unless noted otherwise, values are the number (percent) of patients. Other values are presented as means ± standard deviations.
d
Dose reduction and withdrawal or change to second-line regimen were due to the occurrence of adverse events.